NuVasive (NUVA) Tops Q2 EPS by 16c

NuVasive (NASDAQ: NUVA) reported Q2 EPS of $0.60, $0.16 better than the analyst estimate of $0.44. Revenue for the quarter came in at $294.8 million versus the consensus estimate of $285.08 million.

"NuVasive continued to see the spine market stabilize throughout the second quarter, providing us the opportunity to help more surgeons and patients around the globe. Our continued investments in the cervical and anterior procedural segments and our international commercial organization are advancing both our near- and long-term growth strategy," said J. Christopher Barry, chief executive officer of NuVasive. "Following our latest CE certification, the Pulse platform clinical evaluations and surgeon feedback have exceeded our expectations. The ability for multiple technologies to be utilized in a single, integrated platform enables surgeons to increase surgical reproducibility—a pivotal step in how NuVasive is transforming spine surgery."

For earnings history and earnings-related data on NuVasive (NUVA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity to acquire Harte Hanks for $5 per share in cash and stock
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c